Focused On-demand Library for Xylosyltransferase 2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q9H1B5

UPID:
XYLT2_HUMAN

ALTERNATIVE NAMES:
Peptide O-xylosyltransferase 1; Xylosyltransferase II

ALTERNATIVE UPACC:
Q9H1B5; Q6UY41; Q86V00

BACKGROUND:
The enzyme Xylosyltransferase 2, with alternative names Peptide O-xylosyltransferase 1 and Xylosyltransferase II, catalyzes the essential first step in the synthesis of key proteoglycans. These proteoglycans are vital for the formation of chondroitin sulfate, heparan sulfate, and dermatan sulfate, contributing to the structural integrity and function of the extracellular matrix.

THERAPEUTIC SIGNIFICANCE:
Involvement of Xylosyltransferase 2 in diseases such as Spondyloocular syndrome and its role as a disease modifier in Pseudoxanthoma elasticum underscores its therapeutic significance. Targeting this enzyme could offer new avenues for the development of treatments for these and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.